Revolution Medicines eyes launch of daraxonrasib for pancreatic cancer awaiting US/EU approval, while advancing zoldonrasib & elironrasib. 2026 expenses raised to $2.2B.
Revolution Medicines executives say they’re ready to launch what is arguably the biopharma industry’s most highly anticipated experimental therapy.
The drug, daraxonrasib, is awaiting an …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.
Revolution Medicines' pancreatic cancer drug has not yet been approved — and already talk has shifted to how (and when) its use…
Revolution Medicines' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial.
Revolution Medicines' Phase 1 data on combining zoldonrasib with daraxonrasib in pancreatic cancer support a planned Phase 3…
The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer.
Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically…
